Cefiderocol: a novel siderophore cephalosporin

@article{Choi2018CefiderocolAN,
  title={Cefiderocol: a novel siderophore cephalosporin},
  author={Justin J. Choi and Matthew William McCarthy},
  journal={Expert Opinion on Investigational Drugs},
  year={2018},
  volume={27},
  pages={193 - 197}
}
ABSTRACT Introduction: The emergence of multidrug-resistant bacterial pathogens has led to a global public health emergency and novel therapeutic options and drug-delivery systems are urgently needed. Cefiderocol is a siderophore cephalosporin antibiotic that has recently been developed to combat a variety of bacterial pathogens, including β-lactam- and carbapenem-resistant organisms. Areas covered: This paper provides an overview of the mutational and plasmid-mediated mechanisms of β-lactam… 
A Novel Antibiotic Agent, Cefiderocol, for Multidrug-Resistant Gram-Negative Bacteria
TLDR
It is concluded that cefiderocol is a potent treatment option for prospective bacterial infections because of its siderophore-like properties and modification at the C-3 and C-7 side-chains produces powerful antibacterial properties against MDR gram-negative bacteria.
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
TLDR
Clinical outcome data are required to assess the effectiveness of cefiderocol for treatment of other Acinetobacter species (non-baumannii complex) and Stenotrophomonas maltophilia at this time, and antimicrobial susceptibility testing of these organisms should be limited to research use in the scenario of limited treatment options.
Monobactams: A Unique Natural Scaffold of Four-Membered Ring Skeleton, Recent Development to Clinically Overcome Infections by Multidrug- Resistant Microbes
TLDR
This review aims to summarize the current knowledge and development of monobactam antibiotics as a broad-spectrum antibacterial scaffolds and includes the novels approaches, that could be followed to design new research projects and reduce the pitfalls in the future development ofmonobactams.
Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria
TLDR
The management of infections due to MDR-GNB is discussed, focusing in particular on current strategies and novel agents with already available results from phase 3 randomized controlled trials.
TonB dependent uptake of β-lactam antibiotics in the opportunistic human pathogen Stenotrophomonas maltophilia
TLDR
It is revealed that attempts to improve penetration of antimicrobials into Gram negative bacteria by conjugating them with TonB substrates is likely to select β-lactam resistance in S. maltophilia, increasing its clinical threat.
Global travel and Gram-negative bacterial resistance; implications on clinical management
TLDR
This review describes key carbapenem-resistant Gram-negative species, changes in current global and regional trends, AR surveillance and reporting, and identifies drivers of change, specifically travel.
FDA approved antibacterial drugs: 2018-2019
TLDR
This review focuses on the novel US FDA approved antibacterial agents in the last two years (2018-2019), with a need and urgency to develop novel antibiotic strategies and drugs to overrun the bacterial resistance to antibiotics.
Antibiotics in the clinical pipeline in October 2019
TLDR
There is still a significant gap in the pipeline for the development of new antibacterials with activity against β-metallolactamases, orally administered with broad spectrum G−ve activity, and new treatments for MDR Acinetobacter and gonorrhea.
Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae
TLDR
The discovery of a novel MBL inhibitor, ANT431, that can potentiate the activity of meropenem (MEM) against a broad range of MBL-producing CRE and restore its efficacy against an Escherichia coli NDM-1-producing strain in a murine thigh infection model is reported.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Siderophore-drug complexes: potential medicinal applications of the 'Trojan horse' strategy.
Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae
TLDR
Killing behaviour of fosfomycin does not only differ between species but also within species and may have an impact on the design of optimal dosing regimens and may limit the use of fOSFomycin as a single drug therapy.
Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
TLDR
Compared to the other drugs tested, cefiderocol was more active, with the exception of colistin and tigecycline showing equivalent activity against certain subgroups of bacteria.
Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
TLDR
In conclusion, renal impairment impacted AUC, CL, and t1/2 without affecting Cmax, and cefiderocol was significantly removed by intermittent hemodialysis.
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
  • H. Wright, R. Bonomo, D. Paterson
  • Medicine, Biology
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2017
Emergence of Klebsiella pneumoniae Carbapenemase-Producing Bacteria
TLDR
The purpose of this review is to identify the various challenges that KPC-producing bacteria present to clinicians, including the need for special techniques for microbiological detection, the potential for nosocomial transmission, and therapeutic challenges related to limited, relatively unproven antimicrobial treatment options.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
TLDR
It is concluded that cefiderocol demonstrated potent in vitro activity against a recent collection of clinical isolates of commonly encountered Gram-negative bacilli, including carbapenem-nonsusceptible isolates.
Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check.
  • K. Bush
  • Biology, Chemistry
    ACS infectious diseases
  • 2015
TLDR
Twenty-four new agents in phase 1, phase 2, or phase 3 clinical development were identified for the potential treatment of infections caused by Gram-negative bacteria, with most are improved iterations of known antibiotic classes, including new aminoglycosides, β-lactamase inhibitors, quinolones, and tetracyclines with greater potency or a broader spectrum of activity.
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model
TLDR
Data derived in the current study will assist with the delineation of MIC susceptibility breakpoints for cefiderocol against these important nosocomial Gram-negative pathogens; however, additional clinical data are required to substantiate these observations.
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
TLDR
The potential utility of cefiderocol for the treatment of lung infections caused by carbapenem-resistant P. pneumoniae strains is suggested and the difference in efficacy achieved by changing the infusion period from 1 h to 3 h was considered to be due to the higher percentage of the dosing interval during which free-drug concentrations were above the MIC.
...
1
2
3
4
5
...